Investment Manager Sells $5.1 Million Worth of LQDA Stock, According to Recent SEC Filing
The Motley Fool
by newsfeedback@fool.com (Jake Lerch)March 4, 2026
Liquidia develops inhaled and injectable therapies for pulmonary arterial hypertension, targeting unmet needs in the U.S. biopharma market.
Verticals
financeinvesting
Originally published on The Motley Fool on 3/4/2026